Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Board Changes

13 Dec 2019 13:21

RNS Number : 8662W
NetScientific PLC
13 December 2019
 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Board Changes

 

 

London, UK - 13 December 2019 - NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces planned changes to its Board of Directors. Barry Wilson will retire from the Board following seven years as Non-Executive Director. John Clarkson joins NetScientific as Non-Executive Director with immediate effect.

 

John brings more than twenty years of commercial expertise in leadership roles including that of CEO, Chairman and Non-Executive Director. He was previously partner in charge of a consultancy division in Cooper Deloitte (now PricewaterhouseCoopers), providing services to a range of blue-chip companies and was subsequently Vice Chairman of Laura Ashley Inc. John is an active investor in start-ups, high-tech and growing businesses.

 

John holds a MBA from Cranfield University, after qualifying as an accountant and is a fellow of the Association of Chartered Certified Accountants.

 

John Eric Clarkson (aged 70) currently holds or has held in the past 5 years the following directorships and partnerships:

Current directorships

Past directorships & partnerships

Heimdall Protective Tech Ltd

Recycling Technologies Ltd

Revival Car Hire Ltd

Wrens Cathedral Ltd

Fox Brothers (Elswick) Ltd

C & C Developments Fleetwood Ltd

Around Town @ Limited

C & C Property Developments Ltd

Development Financial and Management Services Limited

 

In addition, Mr. Clarkson was until 31 July 2019 a director of Wroxall Abbey Estate Limited, which was put in to administration on 22 October 2019. The process of administration is ongoing and the sale of assets of the Company is not finalised, and consequently the level of unsatisfied creditors is currently unknown.

 

No further disclosure is required under Paragraph (g) to Schedule Two of the AIM Rules for Companies.

 

Sir Richard Sykes, Chairman of NetScientific, said: "We would like to thank Barry for his significant contributions to the Company. He has provided great strategic insight and direction during his time on the Board and we wish him well for his future. At the same time, we are delighted to welcome John to NetScientific. His commercial experience will be extremely valuable as the Company continues to drive value for its shareholders."

 

# # #

 

For more information, please contact:

 

  NetScientific

Ian Postlethwaite, CEO / CFO

Tel: +44 (0)20 3514 1800

WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel

Tel: +44 (0)20 7220 1666

MO PR ADVISORY (Press Contact)

Mo Noonan

Tel: +44 (0)78 7644 4977

 

 

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. 

 

For more information, please visit the website at www.NetScientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOATJBJTMBBBBRL
Date   Source Headline
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
27th Jun 20228:30 amRNSHolding(s) in Company
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.